Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Ying Xue; Yunyu Mao; Qibin Liao; Chen Zhao; Xiaoyan Zhang; Jianqing Xu

doi:10.3791/66697

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

JoVE Journal
Cancer Research

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Cancer Research

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Full Text

1,504 Views

09:12 min

June 14, 2024

DOI: 10.3791/66697-v

Ying Xue*¹, Yunyu Mao*², Qibin Liao³, Chen Zhao⁴, Xiaoyan Zhang^1,2,4, Jianqing Xu^1,2,4

¹Institutes of Biomedical Sciences,Fudan University, ²Clinical Center of Biotherapy at Zhongshan Hospital,Fudan University, ³Department of Oncology and Bio-therapeutic Center, Shenzhen Third People's Hospital,Southern University of Science and Technology, ⁴Shanghai Public Health Clinical Center,Fudan University

Overview

This article presents a protocol for generating hypoxia-sensitive chimeric antigen receptor (CAR)-T cells and verifying their functionality. The focus is on the lentivirus-based generation of these CAR-T cells, emphasizing their hypoxia-dependent expression and selective cytotoxicity against tumors.

Key Study Components

Area of Science

Cancer Immunotherapy
Chimeric Antigen Receptor (CAR) Technology
Hypoxia in Tumor Microenvironment

Background

CAR T-cell therapy is a promising approach in cancer treatment.
Hypoxia is a common feature of the tumor microenvironment that can affect therapy outcomes.
Improving the safety and efficacy of CAR T-cells is crucial for better patient outcomes.
This research explores hypoxia-sensitive CAR T-cells as a novel strategy.

Purpose of Study

To develop a protocol for creating hypoxia-sensitive CAR-T cells.
To validate the functionality of these CAR-T cells in hypoxic conditions.
To enhance understanding of CAR T-cell behavior in the tumor microenvironment.

Methods Used

Lentivirus-based generation of CAR-T cells.
Characterization of CAR expression under hypoxic conditions.
Assessment of selective cytotoxicity against tumor cells.
Establishment of hypoxia models for evaluation.

Main Results

Successful generation of hypoxia-sensitive CAR-T cells.
Validation of hypoxia-dependent CAR expression.
Demonstration of selective cytotoxicity in hypoxic environments.
Improved safety profile and efficacy in solid tumors.

Conclusions

Hypoxia-sensitive CAR-T cells represent a promising advancement in cancer immunotherapy.
This protocol can aid researchers in developing safer and more effective CAR-T therapies.
Understanding hypoxia's role in CAR T-cell function is essential for future research.

Frequently Asked Questions

What are hypoxia-sensitive CAR-T cells?

Hypoxia-sensitive CAR-T cells are engineered to respond to low oxygen levels in the tumor microenvironment, enhancing their targeting ability.

How does hypoxia affect CAR-T cell therapy?

Hypoxia can influence CAR-T cell functionality and survival, making hypoxia-sensitive designs crucial for effective therapy.

What is the significance of using lentivirus in CAR-T cell generation?

Lentivirus allows for stable integration of CAR genes into T-cells, ensuring long-term expression and functionality.

What are the potential benefits of hypoxia-sensitive CAR-T cells?

They may improve safety profiles and reduce exhaustion, leading to enhanced efficacy in treating solid tumors.

How can researchers evaluate hypoxia-sensitive CAR-T cells?

Researchers can establish hypoxia models to assess CAR expression and cytotoxicity in controlled environments.

What challenges exist in CAR-T cell therapy?

Challenges include managing side effects and ensuring effective targeting of tumor cells without harming healthy tissues.

Here we present a protocol for the generation and functional verification of hypoxia-sensitive chimeric antigen receptor (CAR)-T cells. This protocol presents the lentivirus-based generation of hypoxia-sensitive CAR-T cells and their characterization, including the validation of hypoxia-dependent CAR expression and selective cytotoxicity.

Our research primarily focuses on cancer immunotherapy, particularly in CAR T-cell-based immunotherapy. We have been exploring novel strategies during last 10 years to enable CAR T-cells to specifically target a tumor with minimizing the side effect or even no side effect at all. Novel strategy have been persistently explored to improve the safety and efficacy of the CAR T-cell-based immunotherapy, in particularly by targeting tumor microenvironment, such as hypoxia-conditioned CAR, as exemplified in this protocol.

Interestingly, recent study demonstrated that hypoxia-condition CAR T not only greatly improved the safety profile, but also reduced the CAR T exhaustion and enhanced the efficacy in solid tumors. Hypoxia is a characteristic feature of tumor microenvironment. Our research aims to help researchers in the field of cancer immunotherapy understand the concept of hypoxia-sensitive CAR T-cells, their construction and how to establish hypoxia models for evaluation.

View the full transcript and gain access to thousands of scientific videos